Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Alfred I. Neugut; Grace Clarke Hillyer; Lawrence H. Kushi; Lois Lamerato; Nicole Leoce; Christine B. Ambrosone; Dana H. Bovbjerg; Jeanne S. Mandelblatt; Dawn L. Hershman

doi:10.1007/s12282-014-0543-1

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Alfred I. Neugut, Grace Clarke Hillyer, Lawrence H. Kushi, Lois Lamerato, Nicole Leoce, Christine B. Ambrosone, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Dawn L. Hershman

Research output: Contribution to journal › Article

4 Scopus citations

Abstract

One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

Original language	English (US)
Pages (from-to)	780-785
Number of pages	6
Journal	Breast Cancer
Volume	21
Issue number	6
DOIs	https://doi.org/10.1007/s12282-014-0543-1
State	Published - 2014
Externally published	Yes

Keywords

Adherence
Adjuvant therapy
Breast cancer
Early discontinuation
Non-initiation
Trastuzumab

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Access to Document

10.1007/s12282-014-0543-1

Fingerprint Dive into the research topics of 'Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer'. Together they form a unique fingerprint.

Cite this

Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., & Hershman, D. L. (2014). Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer, 21(6), 780-785. https://doi.org/10.1007/s12282-014-0543-1

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. / Neugut, Alfred I.; Hillyer, Grace Clarke; Kushi, Lawrence H.; Lamerato, Lois; Leoce, Nicole; Ambrosone, Christine B.; Bovbjerg, Dana H.; Mandelblatt, Jeanne S.; Hershman, Dawn L.

In: Breast Cancer, Vol. 21, No. 6, 2014, p. 780-785.

Research output: Contribution to journal › Article

@article{401531ddc6684129a67a58d4315d45a7,

title = "Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer",

abstract = "One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.",

keywords = "Adherence, Adjuvant therapy, Breast cancer, Early discontinuation, Non-initiation, Trastuzumab",

author = "Neugut, {Alfred I.} and Hillyer, {Grace Clarke} and Kushi, {Lawrence H.} and Lois Lamerato and Nicole Leoce and Ambrosone, {Christine B.} and Bovbjerg, {Dana H.} and Mandelblatt, {Jeanne S.} and Hershman, {Dawn L.}",

year = "2014",

doi = "10.1007/s12282-014-0543-1",

language = "English (US)",

volume = "21",

pages = "780--785",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

number = "6",

}

TY - JOUR

T1 - Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

AU - Neugut, Alfred I.

AU - Hillyer, Grace Clarke

AU - Kushi, Lawrence H.

AU - Lamerato, Lois

AU - Leoce, Nicole

AU - Ambrosone, Christine B.

AU - Bovbjerg, Dana H.

AU - Mandelblatt, Jeanne S.

AU - Hershman, Dawn L.

PY - 2014

Y1 - 2014

N2 - One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

AB - One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

KW - Adherence

KW - Adjuvant therapy

KW - Breast cancer

KW - Early discontinuation

KW - Non-initiation

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84939882871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939882871&partnerID=8YFLogxK

U2 - 10.1007/s12282-014-0543-1

DO - 10.1007/s12282-014-0543-1

M3 - Article

C2 - 24902664

AN - SCOPUS:84939882871

VL - 21

SP - 780

EP - 785

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 6

ER -